Safety Assessment of Apoaequorin Published in Regulatory Toxicology and Pharmacology
Madison, WI (PRWEB) April 30, 2014 -- Quincy Bioscience, a recognized leading bioscience company in the state of Wisconsin, is pleased to announce the publication of an additional safety assessment study of apoaequorin in Regulatory Toxicology and Pharmacology, an international journal published by the International Society of Regulatory Toxicology and Pharmacology. The journal reports on scientific information and experimental data with the perspective of protecting human health and the environment.
The objective of the study was to investigate the allergenic potential effects of apoaequorin. The results show that apoaequorin is non-allergenic and safe for consumption, concluding, “The results from the bioinformatics searches with the apoaequorin sequence show the protein is not a known allergen and not likely to cross-react with known allergens.”
To meet the growing consumer demand for products to improve cognitive function, Quincy Bioscience has successfully achieved large scale production of the protein for inclusion in the Prevagen brand of dietary supplements. The study commented on this fact stating, “A calcium-binding protein, apoaequorin, has shown potential utility in a broad spectrum of applications for human health and well-being.”
This is the second published apoaequorin safety study. President Mark Underwood commented, “The safety of the aequorin/apoaequorin complex goes back over 50 years now since its discovery at the Friday Harbor Laboratories. The protein has been tested at levels several thousand times that of the expected amount to be consumed within a daily supply of Prevagen.” Mr. Underwood added, “Prevagen continues to have a great track record of safety without significant side effects from daily usage. The protein in Prevagen is one of those unique finds from nature that provides great hope for all of us with memory and brain health concerns.”
Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health. Apoaequorin is included in the dietary supplement Prevagen. It is used to improve mild memory loss associated with aging.
To learn more about the study, visit the journal of Regulatory Toxicology and Pharmacology. To obtain more information on apoaequorin, please visit the Prevagen website.
About Quincy Bioscience:
Quincy Bioscience is a biotechnology company based in Madison, Wis. that focuses on the discovery, development and commercialization of novel technologies to support good health in aging. The company’s products focus on supporting memory and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Todd Olson, Quincy Bioscience, http://www.quincybioscience.com, 608-827-8134, [email protected]
Share this article